Literature DB >> 8469335

The natural history of amyotrophic lateral sclerosis and the use of natural history controls in therapeutic trials.

J Pradas1, L Finison, P L Andres, B Thornell, D Hollander, T L Munsat.   

Abstract

We analyzed the natural history of amyotrophic lateral sclerosis in 277 patients. Our goal was to develop a better understanding of the clinical disease and thus improve the design of therapeutic trials. The Tufts Quantitative Neuromuscular Exam (TQNE) was used as the primary assessment instrument. Our analysis suggested that although more observations are desirable, six monthly TQNEs were adequate to establish the rate of disease progression. We observed a spectrum of deterioration rates without definable subgroups. The striking linearity of deterioration was confirmed. We found a high correlation between deterioration rates in arm and leg strength for individual patients, but a wide range between different patients. Sex and the age at clinical onset did not affect the deterioration rate. As compared with patients without a positive family history, those with other affected family members had a slower loss in arm but not leg strength. We propose that natural history controls can be used effectively in the design of ALS therapeutic trials.

Entities:  

Mesh:

Year:  1993        PMID: 8469335     DOI: 10.1212/wnl.43.4.751

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  12 in total

1.  Progression in ALS is not linear but is curvilinear.

Authors:  Paul H Gordon; Bin Cheng; Francois Salachas; Pierre-Francois Pradat; Gaelle Bruneteau; Philippe Corcia; Lucette Lacomblez; Vincent Meininger
Journal:  J Neurol       Date:  2010-06-08       Impact factor: 4.849

Review 2.  ALS motor phenotype heterogeneity, focality, and spread: deconstructing motor neuron degeneration.

Authors:  John M Ravits; Albert R La Spada
Journal:  Neurology       Date:  2009-09-08       Impact factor: 9.910

Review 3.  Amyotrophic lateral sclerosis: current and future treatment strategies.

Authors:  B W Festoff
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

Review 4.  Clinical approach to the diagnostic evaluation of hereditary and acquired neuromuscular diseases.

Authors:  Craig M McDonald
Journal:  Phys Med Rehabil Clin N Am       Date:  2012-08       Impact factor: 1.784

Review 5.  A systematic review of the incidence and prevalence of long-term neurological conditions in the UK.

Authors:  Thomas Hoppitt; Hardev Pall; Mel Calvert; Paramjit Gill; Guiqing Yao; Jill Ramsay; Gill James; Jacky Conduit; Cath Sackley
Journal:  Neuroepidemiology       Date:  2010-11-17       Impact factor: 3.282

Review 6.  The epidemiology and treatment of ALS: focus on the heterogeneity of the disease and critical appraisal of therapeutic trials.

Authors:  Ettore Beghi; Adriano Chiò; Philippe Couratier; Jesùs Esteban; Orla Hardiman; Giancarlo Logroscino; Andrea Millul; Douglas Mitchell; Pierre-Marie Preux; Elisabetta Pupillo; Zorica Stevic; Robert Swingler; Bryan J Traynor; Leonard H Van den Berg; Jan H Veldink; Stefano Zoccolella
Journal:  Amyotroph Lateral Scler       Date:  2010-08-11

7.  Continuous response variable trial design in motor neuron disease: long term treatment with a TRH analogue (RX77368).

Authors:  A Goonetilleke; R J Guiloff
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-02       Impact factor: 10.154

8.  Speech in ALS: Longitudinal Changes in Lips and Jaw Movements and Vowel Acoustics.

Authors:  Yana Yunusova; Jordan R Green; Mary J Lindstrom; Gary L Pattee; Lorne Zinman
Journal:  J Med Speech Lang Pathol       Date:  2013-03

Review 9.  Prognostic factors in ALS: A critical review.

Authors:  Adriano Chiò; Giancarlo Logroscino; Orla Hardiman; Robert Swingler; Douglas Mitchell; Ettore Beghi; Bryan G Traynor
Journal:  Amyotroph Lateral Scler       Date:  2009 Oct-Dec

Review 10.  Therapeutic exercise for people with amyotrophic lateral sclerosis or motor neuron disease.

Authors:  Vanina Dal Bello-Haas; Julaine M Florence
Journal:  Cochrane Database Syst Rev       Date:  2013-05-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.